Read More

AbCellera and Its Collaborators Released New Preclinical Data Confirming That the Investigational Antibody Bebtelovimab Maintains Both Full and Potent Neutralization Activity Against the Omicron Variant and All Other Known SARS-COV-2 Variants of Concer…

AbCellera and its collaborators released new preclinical data showing the pseudovirus neutralization status of its two monoclonal antibodies, bamlanivimab and bebtelovimab (also known as LY-CoV1404), against the Omicron variant.